Evidence map›Paper›PMID 40155575›Full record

ArticleBreast cancer research and treatment2025

Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer.

M Braun, M Hamann, C Hanusch, A Andrulat, E Bensmann, M Pölcher, M Beer, E Huber

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

M BraunBreast Cancer Center, Department of Gynecology, Red Cross Hospital Munich, Taxisstrasse 3, 80637, Munich, Germany. Michael.braun@swmbrk.de.
M HamannBreast Cancer Center, Department of Gynecology, Red Cross Hospital Munich, Taxisstrasse 3, 80637, Munich, Germany.
C HanuschBreast Cancer Center, Department of Gynecology, Red Cross Hospital Munich, Taxisstrasse 3, 80637, Munich, Germany.
A AndrulatBreast Cancer Center, Department of Gynecology, Red Cross Hospital Munich, Taxisstrasse 3, 80637, Munich, Germany.
E BensmannBreast Cancer Center, Department of Gynecology, Red Cross Hospital Munich, Taxisstrasse 3, 80637, Munich, Germany.
M PölcherBreast Cancer Center, Department of Gynecology, Red Cross Hospital Munich, Taxisstrasse 3, 80637, Munich, Germany.
M BeerDepartment of Pathology, Red Cross Hospital Munich, Munich, Germany.
E HuberDepartment of Pathology, Red Cross Hospital Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe CPS + EG score, widely used for risk assessment in high-risk HR + /HER2-early breast cancer following neoadjuvant chemotherapy (NAC), integrates clinical and pathological staging, estrogen receptor status, and nuclear grading (nG). However, histological grading (hG) is often used in clinical practice due to better availability. This study aims to assess the concordance between nG and hG and examine their impact on CPS + EG scores.

methodsA retrospective analysis was conducted at the Red Cross Hospital Munich with two cohorts. Cohort 1 included 610 consecutively treated patients in 2022 to evaluate the concordance of nG and hG scores. Cohort 2 involved 106 high-risk patients treated between 2019 and 2022, comparing CPS + EG scores calculated using nG versus hG values.

resultsIn Cohort 1, nG and hG were discordant in 31.2% of cases, with nG3 classifications outnumbering hG3. Cohort 2 showed a similar discordance rate of 33.0%, with more tumors classified as nG3 (52.8%) than hG3 (36.8%). Among non-pCR patients, a CPS + EG score of ≥ 3 was found in 29.7% of cases with nG, versus 19.0% with hG, indicating hG may underestimate risk.

conclusionUsing hG instead of nG for CPS + EG calculations may underestimate risks related to distant metastasis-free and disease-specific survival, suggesting a potential need for nG prioritization in clinical risk assessments.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedBiomarkers, TumorFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingPrognosisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesRisk AssessmentBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerCPS + EG ScoreGradingRisk stratification

Identifiers

PMID40155575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.